Skip to main content

Advertisement

SpringerLink
Log in

Mediator of DNA damage checkpoint protein 1 (MDC1) expression as a prognostic marker for nodal recurrence in early-stage breast cancer patients treated with breast-conserving surgery and radiation therapy

  • Preclinical study
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

The mediator of DNA damage checkpoint protein 1 (MDC1) regulates cell cycle checkpoints and recruits repair proteins to sites of double-stranded DNA damage using its BRCA1 carboxy-terminal (BRCT) domains. MDC1 under-expression has been associated with radiosensitivity in cells. The purpose of this study was to evaluate the clinico-pathologic and prognostic significance of MDC1 expression in a cohort of early-stage breast cancer patients treated with breast conservation therapy. Paraffin specimens from 489 women with early-stage breast cancer treated with breast conservation therapy were constructed into tissue microarrays. The arrays were stained for estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and MDC1. This was correlated with clinico-pathologic factors and outcomes. MDC1 expression was evaluable in 351 cases (72%). Decreased MDC1 expression was found to be correlated with nodal failure (P = 0.05), but not ipsilateral breast relapse-free survival (IBRFS), distant metastasis-free survival (DMFS), or overall survival (OS). Subset analysis in node-negative patients revealed that decreased MDC1 expression predicted for nodal failure (P < 0.01). Our study is the first to assess the clinico-pathologic and prognostic significance of MDC1 expression in patients with early-stage breast cancer treated with lumpectomy and radiotherapy. MDC1 under-expression predicted for nodal failure, but not for IBRFS, DM, or OS. The role of other proteins involved in the DNA damage repair pathway and their effects on MDC1 expression, as well as the level of MDC1 expression in patients with BRCA1 mutations warrant further investigation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Haffty BG, Glazer PM (2003) Molecular markers in clinical radiation oncology. Oncogene 22(37):5915–5925

    Article  PubMed  CAS  Google Scholar 

  2. Goyal S et al (2009) Clinicopathologic significance of excision repair cross-complementation 1 expression in patients treated with breast-conserving surgery and radiation therapy. Int J Radiat Oncol Biol Phys 76(3):679–684

    PubMed  Google Scholar 

  3. Yang Q, Moran MS, Haffty BG (2009) Bcl-2 expression predicts local relapse for early-stage breast cancer receiving conserving surgery and radiotherapy. Breast Cancer Res Treat 115(2):343–348

    Article  PubMed  CAS  Google Scholar 

  4. Goldberg M et al (2003) MDC1 is required for the intra-S-phase DNA damage checkpoint. Nature 421(6926):952–956

    Article  PubMed  CAS  Google Scholar 

  5. Stewart GS et al (2003) MDC1 is a mediator of the mammalian DNA damage checkpoint. Nature 421(6926):961–966

    Article  PubMed  CAS  Google Scholar 

  6. Lou Z et al (2006) MDC1 maintains genomic stability by participating in the amplification of ATM-dependent DNA damage signals. Mol Cell 21(2):187–200

    Article  PubMed  CAS  Google Scholar 

  7. Lou Z et al (2003) Mediator of DNA damage checkpoint protein 1 regulates BRCA1 localization and phosphorylation in DNA damage checkpoint control. J Biol Chem 278(16):13599–13602

    Article  PubMed  CAS  Google Scholar 

  8. Rai R et al (2008) Differential regulation of centrosome integrity by DNA damage response proteins. Cell Cycle 7(14):2225–2233

    Article  PubMed  CAS  Google Scholar 

  9. Bartkova J et al (2007) DNA damage response mediators MDC1 and 53BP1: constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours. Oncogene 26(53):7414–7422

    Article  PubMed  CAS  Google Scholar 

  10. D’Assoro AB et al (2002) Amplified centrosomes in breast cancer: a potential indicator of tumor aggressiveness. Breast Cancer Res Treat 75(1):25–34

    Article  PubMed  Google Scholar 

  11. Stucki M, Jackson SP (2004) MDC1/NFBD1: a key regulator of the DNA damage response in higher eukaryotes. DNA Repair (Amst) 3(8–9):953–957

    Article  CAS  Google Scholar 

  12. Clarke M et al (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366(9503):2087–2106

    PubMed  CAS  Google Scholar 

  13. Recht A, Houlihan MJ (1995) Conservative surgery without radiotherapy in the treatment of patients with early-stage invasive breast cancer. A review. Ann Surg 222(1):9–18

    Article  PubMed  CAS  Google Scholar 

  14. Haffty BG et al (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24(36):5652–5657

    Article  PubMed  Google Scholar 

  15. Haffty BG, Fischer D, Fischer JJ (1990) Regional nodal irradiation in the conservative treatment of breast cancer. Int J Radiat Oncol Biol Phys 19(4):859–865

    Article  PubMed  CAS  Google Scholar 

  16. Pejavar S, Wilson LD, Haffty BG (2006) Regional nodal recurrence in breast cancer patients treated with conservative surgery and radiation therapy (BCS + RT). Int J Radiat Oncol Biol Phys 66(5):1320–1327

    Article  PubMed  Google Scholar 

  17. McShane LM et al (2006) Reporting recommendations for tumor marker prognostic studies (REMARK). Breast Cancer Res Treat 100(2):229–235

    Article  PubMed  Google Scholar 

  18. Inoue K et al (2008) NFBD1/MDC1 stabilizes oncogenic MDM2 to contribute to cell fate determination in response to DNA damage. Biochem Biophys Res Commun 371(4):829–833

    Article  PubMed  CAS  Google Scholar 

  19. Coster G et al (2007) The DNA damage response mediator MDC1 directly interacts with the anaphase-promoting complex/cyclosome. J Biol Chem 282(44):32053–32064

    Article  PubMed  CAS  Google Scholar 

  20. Xu X, Stern DF (2003) NFBD1/MDC1 regulates ionizing radiation-induced focus formation by DNA checkpoint signaling and repair factors. FASEB J 17(13):1842–1848

    Article  PubMed  CAS  Google Scholar 

  21. Nakanishi M et al (2007) NFBD1/MDC1 associates with p53 and regulates its function at the crossroad between cell survival and death in response to DNA damage. J Biol Chem 282(31):22993–23004

    Article  PubMed  CAS  Google Scholar 

  22. Peng A, Chen PL (2003) NFBD1, like 53BP1, is an early and redundant transducer mediating Chk2 phosphorylation in response to DNA damage. J Biol Chem 278(11):8873–8876

    Article  PubMed  CAS  Google Scholar 

  23. Wilson KA, Stern DF (2008) NFBD1/MDC1, 53BP1 and BRCA1 have both redundant and unique roles in the ATM pathway. Cell Cycle 7(22):3584–3594

    Article  PubMed  CAS  Google Scholar 

  24. Gowen LC et al (1998) BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science 281(5379):1009–1012

    Article  PubMed  CAS  Google Scholar 

  25. Xu X et al (1999) Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell 3(3):389–395

    Article  PubMed  CAS  Google Scholar 

  26. Xu B, Kim S, Kastan MB (2001) Involvement of Brca1 in S-phase and G(2)-phase checkpoints after ionizing irradiation. Mol Cell Biol 21(10):3445–3450

    Article  PubMed  CAS  Google Scholar 

Download references

Conflicts of interest statement

The authors report no disclosures or conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, UMDNJ-Robert Wood Johnson Medical School and The Cancer Instititute of New Jersey, 195 Little Albany Street, New Brunswick, NJ, 08903, USA

    Akshar N. Patel, Sharad Goyal, Hao Wu, Devora Schiff & Bruce G. Haffty

  2. Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT, USA

    Meena S. Moran

Authors
  1. Akshar N. Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sharad Goyal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hao Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Devora Schiff
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Meena S. Moran
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bruce G. Haffty
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sharad Goyal.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Patel, A.N., Goyal, S., Wu, H. et al. Mediator of DNA damage checkpoint protein 1 (MDC1) expression as a prognostic marker for nodal recurrence in early-stage breast cancer patients treated with breast-conserving surgery and radiation therapy. Breast Cancer Res Treat 126, 601–607 (2011). https://doi.org/10.1007/s10549-010-0960-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-010-0960-6

Keywords

Search

Navigation